Literature DB >> 517234

The significant reduction of high molecular weight-kininogen in synovial fluid of patients with active rheumatoid arthritis.

K Sawai, S Niwa, M Katori.   

Abstract

It has been proposed that kinin system was implicated in inflammatory joint diseases such as rheumatoid arthritis. Our present work provides further support on the involvement of the kinin system. In osteoarthritis patients, the total, high molecular weight (HMW)-, and low molecular weight (LMW)-kininogen levels in synovial fluid were not different from those in plasma. On the contrary, in rheumatoid patients, HMW-kininogen level in synovial fluid was significantly lower than that in plasma, whereas LMW-kininogen level in synovial fluid was not different from that in plasma. The reduction of HMW-kininogen level in synovial fluid was much more marked in active cases of those who showed high blood sedimentation rate and high C-reactive protein value. Furthermore, the reduction was closely related to the clinical severity. In active rheumatoid patients, HMW-kininogen level was further reduced in the synovial fluid after withdrawal of indomethacin.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 517234

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  3 in total

1.  Pro-inflammatory properties of the kallikrein-kinin system: potential for new drug therapy.

Authors:  J N Sharma; A P Yusof
Journal:  Inflammopharmacology       Date:  1998       Impact factor: 4.473

2.  Augmented plasma and tissue kallikrein like activity in synovial fluid of patients with inflammatory articular diseases.

Authors:  N Volpe-Júnior; E A Donadi; I F Carvalho; M L Reis
Journal:  Inflamm Res       Date:  1996-04       Impact factor: 4.575

3.  An Extensive Study of the Functional Polymorphisms of Kinin-Kallikrein System in Rheumatoid Arthritis Susceptibility.

Authors:  Anthoula Chatzikyriakidou; Paraskevi V Voulgari; Alexandros A Drosos
Journal:  Arch Rheumatol       Date:  2017-09-13       Impact factor: 1.472

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.